Off-label use of recombinant factor VIIa: why we need better drug monitoring
- PMID: 21220460
- PMCID: PMC3017248
- DOI: 10.1503/cmaj.101842
Off-label use of recombinant factor VIIa: why we need better drug monitoring
Comment on
-
Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis.CMAJ. 2011 Jan 11;183(1):E9-19. doi: 10.1503/cmaj.100408. Epub 2010 Nov 15. CMAJ. 2011. PMID: 21078742 Free PMC article.
References
-
- Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791–800 - PubMed
-
- European Medicines Agency NovoSeven. London (UK): The Agency; 2010. Available: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000... (accessed 2010 Dec. 10).
-
- Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879. - PubMed
-
- The Haemostasis Registry — How far have we come and what do we have to show for it? Victoria (Australia): Monash University; 2008. Available:www.med.monash.edu.au/epidemiology/traumaepi/workshop09.html (accessed 2010 Dec. 10).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical